Nitroprusside — Membership Pricing

Other medications in Heart & Cardiovascular

• Olmesartan
• Perindopril
• Pindolol
• Pitavastatin
• Pravastatin
• Propafenone
• Quinapril
• Ramipril

About Nitroprusside

Nitroprusside is a powerful, fast-acting medication used in critical care settings to rapidly lower dangerously high blood pressure. When minutes count, access to essential medications like nitroprusside is vital. TheDrugClub is dedicated to helping members manage their prescription costs, ensuring they can access life-saving treatments like this with potential savings.

Nitroprusside is primarily used in acute, life-threatening situations where blood pressure needs to be reduced immediately. This includes hypertensive emergencies (severe hypertension with organ damage), acute heart failure with severe pulmonary edema, and controlled hypotension during surgery to reduce bleeding. It's not a medication for chronic high blood pressure management but rather a short-term, intensive care treatment.

Sodium nitroprusside works by releasing nitric oxide (NO) in the bloodstream. Nitric oxide is a potent vasodilator, meaning it relaxes and widens blood vessels throughout the body. This relaxation of both arteries and veins reduces the resistance against which the heart has to pump blood (afterload) and decreases the amount of blood returning to the heart (preload). The result is a rapid and significant drop in blood pressure, improving blood flow and reducing strain on the heart and other organs. Because of its rapid action and short duration, it must be administered intravenously and continuously monitored in a hospital setting.

As a critical care medication administered in hospital settings, nitroprusside is typically not purchased at a retail pharmacy for outpatient use. Its cost is usually bundled into hospital charges for emergency treatment or intensive care. However, the underlying cost of the drug itself can be substantial, often hundreds to thousands of dollars per dose or course of treatment, depending on the duration and facility. These costs contribute to the overall hospital bill, which can be a significant financial burden for patients, even with insurance. For individuals without adequate insurance or facing high deductibles, understanding how to

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Nitroprusside is approved for (FDA label)

Sodium nitroprusside injection is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. Concomitant longer-acting antihypertensive medication should be administered so that the duration of treatment with sodium nitroprusside can be minimized. Sodium nitroprusside injection is also indicated for producing controlled hypotension in order to reduce bleeding during surgery. Sodium nitroprusside injection is also indicated for the treatment of acute congestive heart failure.

Source: Read the full FDA label on DailyMed. Label effective date: August 10, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Nitroprusside (FDA label)

Sodium nitroprusside injection is not suitable for direct injection. The solution must be further diluted in sterile 5% dextrose injection before infusion. Sodium nitroprusside can cause precipitous decreases in blood pressure (see DOSAGE AND ADMINISTRATION ). In patients not properly monitored, these decreases can lead to irreversible is chemic injuries or death. Sodium nitroprusside should be used only when available equipment and personnel allow blood pressure to be continuously monitored. Except when used briefly or at low (< 2 mcg/kg/min) infusion rates, sodium nitroprusside gives rise to important quantities of cyanide ion, which can reach toxic, potentially lethal levels (see WARNINGS ). The usual dose rate is 0.5 to 10 mcg/kg/min, but infusion at the maximum dose rate should never last more than 10 minutes. If blood pressure has not been adequately controlled after 10 minutes of infusion at the maximum rate, administration of sodium nitroprusside should be terminated immediately. Although acid-base balance and venous oxygen concentration should be monitored and may indicate cyanide toxicity, these laboratory tests provide imperfect guidance.

Source: FDA prescribing information (DailyMed). Set ID: 5a599880-c133-44ef-a9f2-bd1b681563be. SPL document ID: 58ae93d9-ac6f-c677-e063-6294a90a6c58. Label effective date: August 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Nitroprusside (FDA label)

The most important adverse reactions to sodium nitroprusside are the avoidable ones of excessive hypotension and cyanide toxicity, described above under WARNINGS . The adverse reactions described in this section develop less rapidly and, as it happens, less commonly. Methemoglobinemia: As described in CLINICAL PHARMACOLOGY above, sodium nitroprusside infusions can cause sequestration of hemoglobin as methemoglobin. The back-conversion process is normally rapid, and clinically significant methemoglobinemia (>10%) is seen only rarely in patients receiving sodium nitroprusside.

Source: FDA prescribing information (DailyMed). Set ID: 5a599880-c133-44ef-a9f2-bd1b681563be. SPL document ID: 58ae93d9-ac6f-c677-e063-6294a90a6c58. Label effective date: August 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Nitroprusside (FDA label)

Sodium nitroprusside should not be used in the treatment of compensatory hypertension, where the primary hemodynamic lesion is aortic coarctation or arteriovenous shunting. Sodium nitroprusside should not be used to produce hypotension during surgery in patients with known inadequate cerebral circulation, or in moribund patients (A.S.A. Class 5E) coming to emergency surgery. Patients with congenital (Leber’s) optic atrophy or with tobacco amblyopia have unusually high cyanide/thiocyanate ratios. These rare conditions are probably associated with defective or absent rhodanase, and sodium nitroprusside should be avoided in these patients. Sodium nitroprusside should not be used for the treatment of acute congestive heart failure associated with reduced peripheral vascular resistance such as high-output heart failure that may be seen in endotoxic sepsis.

Source: FDA prescribing information (DailyMed). Set ID: 5a599880-c133-44ef-a9f2-bd1b681563be. SPL document ID: 58ae93d9-ac6f-c677-e063-6294a90a6c58. Label effective date: August 10, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.